切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2015, Vol. 11 ›› Issue (06) : 789 -792. doi: 10.3877/cma.j.issn.1673-5250.2015.06.023

所属专题: 专题评论 文献

综述

血清microRNA在妇科恶性肿瘤临床诊断及其预后评价中的研究进展
何少仪1, 孙小丽1, 罗喜平1,*,*()   
  1. 1. 510010 广州医科大学附属广东省妇幼保健院妇科
  • 收稿日期:2015-07-09 修回日期:2015-11-25 出版日期:2015-12-01
  • 通信作者: 罗喜平

Research progress of serum microRNA in gynecologic malignant tumor clinical application

Shaoyi He1, Xiaoli Sun1, Xiping Luo1()   

  1. 1. Department of Obstetrics and Gynecology, Guangdong Maternal and Child Health Care Hospital, Guangzhou Medical University, Guangzhou 510010, Guangdong Province, China
  • Received:2015-07-09 Revised:2015-11-25 Published:2015-12-01
  • Corresponding author: Xiping Luo
  • About author:
    Corresponding author: Luo Xiping, Email:
引用本文:

何少仪, 孙小丽, 罗喜平. 血清microRNA在妇科恶性肿瘤临床诊断及其预后评价中的研究进展[J]. 中华妇幼临床医学杂志(电子版), 2015, 11(06): 789-792.

Shaoyi He, Xiaoli Sun, Xiping Luo. Research progress of serum microRNA in gynecologic malignant tumor clinical application[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2015, 11(06): 789-792.

微小RNA(miRNA)是一类在人体内广泛分布的内源性非编码RNA,主要在转录后水平对靶基因的表达起调节作用,并在肿瘤的发生、发展中具有癌基因或抑癌基因功能。血清中miRNA表达水平与组织中表达水平相一致,因此可通过检测血清中miRNA水平来诊断疾病和评估病情。本文主要讨论血清miRNA在妇科恶性肿瘤早期诊断和预后评估中的临床应用,并对其研究进展进行综述。

MicroRNA(miRNA) is a class of endogenous non-coding RNA, which wide distribution in human body and primarily regulates the expression of target gene in the post-transcriptional level, and it has the function of oncogenes or tumor suppressor genes in the development of tumors. Expression level of serum miRNA is consistent with expression level in tissues, so we may diagnose the disease and assess pathogenetic condition by detect miRNA expression level in serum.This paper reviews the research progress of serum miRNA in clinical application for early diagnosis and assess prognosis of gynecological malignancies.

[1]
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5):843-854.
[2]
Mitchell PS, Parkin RK, Kroh EM, et al.Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci USA, 2008, 105(30):10513-10518.
[3]
Patel RS, Jakymiw A, Yao B, et al. High resolution of microRNA signatures in human whole saliva[J]. Arch Oral Biol, 2011, 56(12):1506-1513.
[4]
Wang G, Chan ES, Kwan BC, et al. Expression of microRNAs in the urine of patients with bladder cancer[J]. Clin Genitourin Cancer, 2012, 10(2):106-113.
[5]
Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors[J]. Dev Biol, 2007, 302(1):1-12.
[6]
Chung YW, Bae HS, Song JY, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients[J]. Int J Gynecol Cancer, 2013, 23(4):673-679.
[7]
师婕,张林燕.微小RNA-27a在子宫颈鳞癌患者血清和组织中的表达及意义[J].中国妇产科临床杂志,2014,15(2):172-174.
[8]
Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells[J]. BMC Biotechnol, 2007, 7:36.
[9]
Lee YS, Dutta A. MicroRNAs in cancer[J]. Annu Rev Pathol, 2009, 4:199-227.
[10]
Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform[J]. Gynecol Oncol, 2009, 112(1):55-59.
[11]
Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol, 2008, 108(2):402-408.
[12]
Kan CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer[J]. BMC Cancer, 2012, 12:627.
[13]
Guo F, Tian J, Lin Y, et al. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma[J]. J Int Med Res, 2013, 41(5):1456-1461.
[14]
Xu YZ, Xi QH, Ge WL, et al.Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer[J]. Asian Pac J Cancer Prev, 2013, 14(2):1057-1060.
[15]
Hong F, Li Y, Xu Y, et al. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer[J]. J Int Med Res, 2013, 41(1):64-71.
[16]
Zheng H, Zhang L, Zhao Y, et al.Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer[J]. PLoS One, 2013, 8(11):e77853.
[17]
Langhe R, Norris L, Saadeh FA, et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease[J]. Cancer Lett, 2015, 356(2 Pt B):628-636.
[18]
冯朝霞,黄余良,欧阳先辉.卵巢癌患者血浆miRNA水平与顺铂化疗敏感性的相关性研究[J].中国医师杂志,2014,16(7):930-933.
[19]
Torres A, Torres K, Pesci A, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma[J]. BMC Cancer, 2012, 12:369.
[20]
Torres A, Torres K, Pesci A, et al.Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients[J]. Int J Cancer, 2013, 132(7):1633-1645.
[21]
Wang L, Chen YJ, Xu K, et al.Circulating microRNAs as a fingerprint for endometrial endometrioid adenocarcinoma[J]. PLoS One, 2014, 9(10):e110767.
[22]
贾英华.子宫内膜癌患者血清Has-miR-141的表达及其临床意义[D].北京协和医学院,2013.
[23]
谭志琴,刘伏香,唐海林,等.子宫内膜癌患者血清hsa-miR-155的表达及其临床意义[J]. 中华妇产科杂志,2010,45(10):772-774.
[24]
陈玉芬.子宫内膜癌患者血清中miR-155的表达及其临床意义研究[J].中国医药导刊,2014,16(1):160-161.
[25]
Yu J, Wang Y, Dong R, et al.Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion[J]. J Cancer Res Clin Oncol, 2012, 138(4):671-674.
[26]
Juan L, Tong HL, Zhang P, et al.Identification and characterization of novel serum microRNA candidates from deep sequencing in cervical cancer patients[J]. Sci Rep, 2014, 4:6277.
[27]
Chen J, Yao D, Li Y, et al.Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma[J]. Int J Mol Med, 2013, 32(3):557-567.
[28]
Zhao S, Yao D, Chen J, et al.Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer[J]. Genet Test Mol Biomarkers, 2013, 17(8):631-636.
[29]
贺婵娟,姚德生,陈军莹.miR-21在宫颈鳞癌淋巴结转移患者血清中的表达及其临床意义[J].实用医学杂志,2012,28(19):3195-3197.
[30]
Ma Q, Wan G, Wang S, et al.Serum microRNA-205 as a novel biomarker for cervical cancer patients[J]. Cancer Cell Int, 2014, 14:81.
[31]
Keller A, Leidinger P, Bauer A, et al.Toward the blood-borne miRNome of human diseases[J]. Nat Methods, 2011, 8(10):841-843.
[1] 黄泽, 张梓榆, 杨青宇, 赖声清, 李海燕. 乳腺腔镜手术临床应用现状及训练路径[J]. 中华乳腺病杂志(电子版), 2023, 17(02): 122-125.
[2] 贺敬龙, 孙炜, 高明宏, 谢伟, 姜骆永, 何琦非, 岳家吉. 外泌体非编码RNA在骨关节炎发病机制中的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(04): 520-527.
[3] 马敏榕, 李聪, 周勤. 宫颈癌治疗研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 497-504.
[4] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[5] 王璐, 樊杨. 子宫内膜癌相关生物标志物研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 511-516.
[6] 周东杰, 蒋敏, 范海瑞, 高玲玲, 孔祥, 卢丹, 王丽萍. 非编码RNA在卵泡发育成熟中作用及其机制的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 387-393.
[7] 陈荟竹, 郭应坤, 汪昕蓉, 宁刚, 陈锡建. 上皮性卵巢癌"二元论模型"的分子生物学研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 394-402.
[8] 韩春颖, 王婷婷, 李艳艳, 朴金霞. 子宫内膜癌患者淋巴管间隙浸润预测因素研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 403-409.
[9] 刘星辰, 刘娟, 魏宝宝, 刘洁, 刘辉. XIAP与XAF1异常表达与卵巢癌的相关性分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 419-427.
[10] 叶啟发. 生物人工肝血液净化材料研究现状[J]. 中华移植杂志(电子版), 2023, 17(02): 0-.
[11] 袁久莉, 刘丹, 李林藜, 刘晋宇. 毛囊间充质干细胞的基础研究及临床应用[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(03): 189-192.
[12] 王楚风, 蒋安. 原发性肝癌的分子诊断[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 499-503.
[13] 吴绍伟. 迷走神经电刺激术治疗神经系统疾病的应用进展[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(03): 180-184.
[14] 刘迎, 尹嫚, 杨林青, 王云飞. 子宫颈浸润性复层产黏液的癌的诊断学特征并文献复习[J]. 中华诊断学电子杂志, 2023, 11(03): 173-177.
[15] 刘育昕, 王子晗, 张艺馨, 栾永婕, 孟凯. 肾母细胞瘤基因1在卵巢疾病发病机制中的研究进展[J]. 中华诊断学电子杂志, 2023, 11(03): 178-183.
阅读次数
全文


摘要